The startup develops a universal nanoparticle-based radiopharmaceutical platform that delivers targeted radiation directly to cancer cells, enhancing the precision of alpha therapy. This technology enables higher radiation doses to tumors while significantly reducing damage to surrounding healthy tissue, improving treatment effectiveness and patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer treatments often lack precision, leading to damage of healthy tissues surrounding the tumor. This can result in significant side effects and limit the effectiveness of radiation therapy.
Solution
This startup is developing a nanoparticle-based radiopharmaceutical platform designed to deliver targeted radiation directly to cancer cells. By embedding radioactive materials within nanoparticles, the platform aims to enhance the precision of alpha therapy, allowing for higher radiation doses to be delivered to tumors while minimizing damage to surrounding healthy tissue. This targeted approach has the potential to improve treatment effectiveness and patient outcomes by reducing side effects and increasing the therapeutic impact on cancerous cells. The universal nature of the nanoparticle platform allows for the delivery of various radioactive materials, offering flexibility in targeting different types of cancer.
Target Audience
The primary target audience includes oncology researchers, medical professionals specializing in radiation therapy, and cancer patients seeking more effective and less invasive treatment options.
Features
- Universal nanoparticle platform for embedding radioactive materials.
- Targeted delivery of radiation to cancer cells.
- Enhanced precision of alpha therapy.
- Potential for higher radiation doses to tumors.
- Minimized damage to surrounding healthy tissue.